glp-1 and dpp4 GLP 1 Receptor Agonists DPP 4 Inhibitors Mechanism of Action Oral formulation of DPP-4 inhibitor

Food and Drug Administration (FDA) approved aducanumab as the first disease-modifying therapy (DMT) for AD in June 2021, 10 there has been considerable medical and scientific controversy regarding its curative effect

Reyes-Garca R, Moreno-Prez O, Bellido-Castaeda V, Botana Lpez M, Rodrguez-Hervada AD, Fernndez-Garca D

The insurer cited the same cost sustainability concerns that drove BCBS decisions, adding that member premium stability required difficult choices about which therapies the plan could continue to support at current pricing levels

Ultimately, Pfizer discontinued the entire program in April 2025, citing that the risk-benefit profile, including a potential case of drug-induced liver injury (DILI) in a recent study, did not support further development

Bismuth subsalicylate, sold as Pepto-Bismol, is another option

I can only speak to my own experience: with MCAS and its many comorbidities, I have always been medication sensitive, and that sensitivity seems, in this case, to be working in my favour